TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10165553

Group type: EXPERIMENTAL
Intervention: Nicotine replacement patch (Prostep, Lederle Laboratories) with no additional support (Group I, n = 166)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support (Group II, n = 167)
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support and four follow-up calls (Group III, n = 167)
Number of subjects: 509

Group type: COMPARATOR
Intervention: N/A (Control group not explicitly defined)
Number of subjects: 509
Study: 8475816

Group type: EXPERIMENTAL
Intervention: 500 mg fusidic acid (intervention)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 90
Study: 3823635

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional dose of prednisolone
Number of subjects: 10
Study: 30661105

Group type: EXPERIMENTAL
Intervention: CBD alone (400 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: THC alone (8 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: THC combined with low dose CBD (4 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: THC combined with high dose CBD (400 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29110150

Group type: EXPERIMENTAL
Intervention: 30-min, vigorous-intensity treadmill bout 24 hours prior to each of four doxorubicin treatments
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 26872808

Group type: EXPERIMENTAL
Intervention: 3D presentation mode
Number of subjects: 410

Group type: COMPARATOR
Intervention: 2D presentation mode
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Gender (Men vs Women)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Fun factor
Number of subjects: 410

Group type: COMPARATOR
Intervention: Preference for presentation mode
Number of subjects: 410
Study: 24633502

Group type: EXPERIMENTAL
Intervention: Delayed (18)FDG PET/CT imaging at 180 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: (18)FDG PET/CT imaging at 90 minutes
Number of subjects: 40
Study: 22538083

Group type: EXPERIMENTAL
Intervention: special carbohydrate-protein cake (carbohydrate to whey protein 3.5:1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: isocaloric carbohydrate cake
Number of subjects: 9
Study: 20359643

Group type: EXPERIMENTAL
Intervention: Patient Adjustable Warming System (Bair PAWS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Warm Blanket
Number of subjects: 130
Study: 19226891

Group type: EXPERIMENTAL
Intervention: Acupuncture and conventional rehabilitation therapy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy (Control)
Number of subjects: 69
Study: 16253059

Group type: EXPERIMENTAL
Intervention: OptiVu HD3 Heads‐Up goggles
Number of subjects: 12

Group type: COMPARATOR
Intervention: 20-inch Sony Triniton monitor (TV)
Number of subjects: 12
Study: 11919119

Group type: EXPERIMENTAL
Intervention: Chicken-based diet
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 28
Study: 10232685

Group type: EXPERIMENTAL
Intervention: Continued ramipril (1.25 to 5 mg/d)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Switched to ramipril
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continued ramipril (with at least six GFR measurements)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Continued ramipril
Number of subjects: 150
Study: 8975262

Group type: EXPERIMENTAL
Intervention: Formal Characteristic of Behaviour‐Temperamental Questionnaire (FCZ‐KT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wiener‐Testsystem (WT)
Number of subjects: 60
Study: 1769930

Group type: EXPERIMENTAL
Intervention: aztreonam plus flucloxacillin
Number of subjects: 100

Group type: COMPARATOR
Intervention: piperacillin plus gentamicin
Number of subjects: 100
Study: 6287359

Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physostigmine (single IV infusion)
Number of subjects: 0
Study: 29908832

Group type: EXPERIMENTAL
Intervention: CMR-guided LV lead placement
Number of subjects: 99

Group type: COMPARATOR
Intervention: Electrophysiologically guided LV lead placement (EP group)
Number of subjects: 99
Study: 28733869

Group type: EXPERIMENTAL
Intervention: Annual or biennial screening by fecal occult blood testing
Number of subjects: 46551

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 46551
Study: 25444352

Group type: EXPERIMENTAL
Intervention: TECNIS toric IOL (ZCT150)
Number of subjects: 265

Group type: COMPARATOR
Intervention: TECNIS 1-piece control IOL (ZCB00)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Open-label arm (ZCT225, ZCT300, ZCT400)
Number of subjects: 265
Study: 23639793

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antipsychotic trials with adequate allocation concealment, double blinding, higher precision, larger trial size, at least three treatment arms, recent publication, conducted in the United States, and enrollment of inpatients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 21317283

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg daily (titrated to 30 and 60 mg if necessary)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 18574016

Group type: EXPERIMENTAL
Intervention: Unit-based clinical pharmacists in the ICU (full-time)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Unit-based clinical pharmacists in general care units (part-time)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (similar patient care units without unit-based clinical pharmacists)
Number of subjects: 3
Study: 16934685

Group type: EXPERIMENTAL
Intervention: Oltipraz 125 mg daily
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Oltipraz 500 mg weekly
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study: 12220946

Group type: EXPERIMENTAL
Intervention: formoterol (24 microg dry powder)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: formoterol
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 9457093

Group type: EXPERIMENTAL
Intervention: Early amniocentesis (11 mL, between 11(+0) and 12(+6) gestational weeks)
Number of subjects: 4374

Group type: COMPARATOR
Intervention: Midtrimester amniocentesis (20 mL, between 15(+0) and 16(+6) gestational weeks)
Number of subjects: 4374

Group type: EXPERIMENTAL
Intervention: Early amniocentesis
Number of subjects: 4374

Group type: COMPARATOR
Intervention: Midtrimester amniocentesis
Number of subjects: 4374
Study: 8572639

Group type: EXPERIMENTAL
Intervention: Treatment A: 1 mg of GRAN initially and 12 hours after the first dose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Treatment B: a single 2 mg dose of GRAN
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 30
Study: 2404435

Group type: EXPERIMENTAL
Intervention: HBM clinical intervention administered in the ED
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: HBM telephone intervention two to four days after the ED visit
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both HBM clinical and telephone interventions
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 139
Study: 1023957

Group type: EXPERIMENTAL
Intervention: Doxapram 250 mg in dextrose 5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dextrose 5% alone
Number of subjects: 0
Study: 7240103

Group type: EXPERIMENTAL
Intervention: Pretherapy information provided via a printed leaflet included with the application blank for alternate cases.
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Patients who participated in psychotherapy after receiving pretherapy information.
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Patients with health insurance.
Number of subjects: 1300
Study: 31907125

Group type: EXPERIMENTAL
Intervention: Severe OSA group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: All OSA groups
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Stepwise multiple regression analysis
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tt.vBMD of radius
Number of subjects: 83
Study: 29290494

Group type: EXPERIMENTAL
Intervention: High/immeasurable ABI
Number of subjects: 260

Group type: COMPARATOR
Intervention: Intermediate ABI
Number of subjects: 260

Group type: COMPARATOR
Intervention: Low ABI
Number of subjects: 260
Study: 26631085

Group type: EXPERIMENTAL
Intervention: Behavioral self-regulation intervention
Number of subjects: 119

Group type: COMPARATOR
Intervention: Active control condition (attention-placebo support and discussion)
Number of subjects: 119
Study: 24968814

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 90
Study: 22864190

Group type: EXPERIMENTAL
Intervention: Continuous quality improvement program
Number of subjects: 5912

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 5912
Study: 20849938

Group type: EXPERIMENTAL
Intervention: BGP-15 (400mg once daily for 17 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 37
Study: 18179312

Group type: EXPERIMENTAL
Intervention: Visually-impoverished environment training under alcohol (0.65 g/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normal visual environment training under alcohol (0.65 g/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group trained and tested under visually-impoverished condition
Number of subjects: 30
Study: 15766377

Group type: EXPERIMENTAL
Intervention: Pointed-shaped brush head (PBH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard cup-shaped brush head (CBH)
Number of subjects: 40
Study: 12396317

Group type: EXPERIMENTAL
Intervention: Chloroquine plus chlorpheniramine (CQCP)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 131
Study: 10682110

Group type: EXPERIMENTAL
Intervention: GDP-free PD solution
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional PD solution
Number of subjects: 31
Study: 8646568

Group type: EXPERIMENTAL
Intervention: Citrus fragrance
Number of subjects: 12
Study: 2283647

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg (10 patients) and 20 mg (2 patients) twice daily for 8 weeks
Number of subjects: 12
Study: 218427

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoprenaline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 31010372

Group type: EXPERIMENTAL
Intervention: Moderate-intensity acute exercise
Number of subjects: 22
Study: 28187722

Group type: EXPERIMENTAL
Intervention: Home delivery of pre-made healthy family meals
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Home delivery of healthy meal ingredients
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Community kitchens for parents to make healthy meals
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Healthy eating classes
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Cooking demonstrations
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Cookware/flatware delivery
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Bundled intervention (to be determined)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Usual Head Start Exposure
Number of subjects: 512
Study: 24523431

Group type: EXPERIMENTAL
Intervention: Nurse-based case management (individualized follow-up programme with home visits and telephone calls for 1 year)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Nurse-based case management
Number of subjects: 329

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 329
Study: 23896377

Group type: EXPERIMENTAL
Intervention: Adjuvant PCV (Procarbazine, CCNU, Vincristine) chemotherapy
Number of subjects: 368
Study: 21853760

Group type: EXPERIMENTAL
Intervention: Team-centered program on sport nutrition, exercise, and disordered eating consequences (4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 18534415

Group type: EXPERIMENTAL
Intervention: Surface replacement arthroplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Total hip arthroplasty
Number of subjects: 200
Study: 17675341

Group type: EXPERIMENTAL
Intervention: Plasma stored at 4, 21, or 30 degrees C for 1-5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole blood stored at 4, 21, or 30 degrees C for 1-5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 freeze-thaw cycles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Immediate assay
Number of subjects: 10
Study: 15151167

Group type: EXPERIMENTAL
Intervention: Zobo drink (Hibiscus sabdariffa water extract)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1g) administered after zobo drink
Number of subjects: 6

Group type: COMPARATOR
Intervention: Acetaminophen (1g) administered alone
Number of subjects: 6
Study: 12202092

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control mixture
Number of subjects: 13
Study: 9832115

Group type: EXPERIMENTAL
Intervention: High-dose lisinopril-isosorbide dinitrate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established doses of angiotensin-converting enzyme inhibitor and nitrate therapy
Number of subjects: 0
Study: 8607311

Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microgram.kg‐1.min‐1, n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dopamine (2.5 micrograms.kg‐1.min‐1, n = 11)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 35
Study: 2561096

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (O‐GTT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin Secretion Test (IST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delta IST/delta O‐GTT
Number of subjects: 0
Study: 1258516

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxyfedrin
Number of subjects: 28
Study: 31984598

Group type: EXPERIMENTAL
Intervention: Tirzepatide 12 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg-1
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg-2
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 29601789

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF) membrane
Number of subjects: 30

Group type: COMPARATOR
Intervention: Collagen membrane
Number of subjects: 30
Study: 27991604

Group type: EXPERIMENTAL
Intervention: Wall Climbing Intervention (WCI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 35
Study: 25703320

Group type: EXPERIMENTAL
Intervention: Intervention group (10 sessions + 2 booster sessions)
Number of subjects: 1176
Study: 23262999

Group type: EXPERIMENTAL
Intervention: GS-9851 (25 to 800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21636183

Group type: EXPERIMENTAL
Intervention: Oral essential amino acids 4 gr 2 times a day for 8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 41
Study: 18175066

Group type: EXPERIMENTAL
Intervention: E+L+ (10 + 50 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: L+ (50 mg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TT genotype of AGT
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MDA
Number of subjects: 64
Study: 17205814

Group type: EXPERIMENTAL
Intervention: Shenle Capsule (SC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fosinopril
Number of subjects: 70
Study: 14638484

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 12
Study: 11012490

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 38

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 38
Study: 9046509

Group type: EXPERIMENTAL
Intervention: Acute arthroscopic lavage within 10 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional non-operative therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acute MRI
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6-month follow-up MRI
Number of subjects: 30
Study: 1951149

Group type: EXPERIMENTAL
Intervention: Dietary supplement given twice a day providing an average of 10.66 kJ (400 kcal) and 5 g protein/d.
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no dietary supplement).
Number of subjects: 113
Study: 6678543

Group type: EXPERIMENTAL
Intervention: Undrained cholecystectomy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Drained cholecystectomy
Number of subjects: 123
Study: 31561118

Group type: EXPERIMENTAL
Intervention: Repetitive sit‐to‐stand task (RSTS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mental tasks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fatigability (general)
Number of subjects: 24
Study: 29228147

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33.0°C) for 48 hours
Number of subjects: 292

Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C) for 48 hours
Number of subjects: 292
Study: 28969313

Group type: EXPERIMENTAL
Intervention: NIRS-based 'patient-specific' algorithm with restrictive red cell transfusion threshold (haematocrit 18%)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Generic non-NIRS-based algorithm (standard care)
Number of subjects: 204
Study: 26247967

Group type: COMPARATOR
Intervention: n-3 fatty acid supplementation (EPA + DHA) at varying doses (Study 1: 0, 300, 600, 900, and 1800 mg/day; Study 2: 0, 850, and 3400 mg/day)
Number of subjects: 143
Study: 24284085

Group type: EXPERIMENTAL
Intervention: ALA‐induced fluorescence
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enhanced MRI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fluorescence and spectroscopy techniques
Number of subjects: 20
Study: 21415722

Group type: EXPERIMENTAL
Intervention: 80 pps TENS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3 pps TENS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 48
Study: 17611715

Group type: EXPERIMENTAL
Intervention: Paclitaxel alone (total cumulative dose range: 950‐2,475 mg/m2)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Paclitaxel and adriamycin (total cumulative dose range: 700‐2,800 mg/m2)
Number of subjects: 2
Study: 16553681

Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 93

Group type: COMPARATOR
Intervention: Laughter therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 93
Study: 14610097

Group type: EXPERIMENTAL
Intervention: 20 meq/d salt diet
Number of subjects: 199

Group type: COMPARATOR
Intervention: >200 meq/d salt diet
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Salt sensitivity (SS)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Salt resistance
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Erythrocyte cations (Na+i, Ca2+i)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Sodium pump activity
Number of subjects: 199
Study: 11100279

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, metronidazole, and fluconazole
Number of subjects: 134

Group type: COMPARATOR
Intervention: Ciprofloxacin and fluconazole
Number of subjects: 134
Study: 8821692

Group type: EXPERIMENTAL
Intervention: Alprostadil sterile powder (Caverject) 5 micrograms
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alprostadil sterile powder (Caverject) 10 micrograms
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Alprostadil sterile powder (Caverject) 20 micrograms (open fashion)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 7698890

Group type: EXPERIMENTAL
Intervention: dexamethasone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: high‐dose methylprednisolone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: low‐dose methylprednisolone
Number of subjects: 19
Study: 3661613

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g) with indomethacin (50 mg) pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Indomethacin (50 mg) pretreatment
Number of subjects: 8
Study: 29106749

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment simultaneous to periodontal treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cause-related periodontal treatment before orthodontic treatment (Control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27380647

Group type: EXPERIMENTAL
Intervention: Patient storytelling DVD intervention
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Patient storytelling DVD intervention (for 54% of patients who watched the DVD)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study: 23959960

Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 1525
Study: 24373032

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) + Immunoglobulin (IVIG)
Number of subjects: 61
Study: 22416849

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV; TMC278) 25 mg once a day
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once a day
Number of subjects: 1368
Study: 17921372

Group type: COMPARATOR
Intervention: Eucaloric energy intake
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 30% overfeeding
Number of subjects: 25
Study: 16182355

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement (ME; Motivational Interviewing + Carbon Monoxide Feedback)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard Care (AHCPR Guidelines for smoking cessation)
Number of subjects: 273